Journal article · 2023 · Open access
Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study
Frontiers in Immunology, 14, 1267749 · Published 2 October 2023 · DOI 10.3389/fimmu.2023.1267749
In brief
“Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study” is a 2023 journal article by Shuhei Yoshida and 12 co-authors, published in Frontiers in Immunology. OpenAlex counts 24 citations as of 19 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 24
- Most cited in
- 2026 (11)
- Field-weighted impact
- 4.00
- References
- 26
- Authors
- 13
Abstract
Background: The ORAL Surveillance trial showed a potentially higher incidence of malignancy and major adverse cardiovascular events (MACEs) associated with tofacitinib than those associated with tumor necrosis factor (TNF) inhibitors (TNFis). However, few studies have compared the safety of non-TNFis or other Janus kinase (JAK) inhibitors (JAKis). This study was aimed at comparing the incidence rates (IRs) of malignancies and MACEs in patients with rheumatoid arthritis (RA) treated using interleukin-6 (IL-6) inhibitors (IL-6is) or JAKis. Methods: We retrospectively analyzed 427 patients with RA who were treated using an IL-6i (n = 273) or a JAKi (n = 154). We determined the IRs of malignancy and MACEs, and the standardized incidence ratio (SIR) of malignancies and investigated factors related to malignancy and MACEs. After adjusting the clinical characteristic imbalance by propensity score matching (PSM), we compared the IRs of adverse events between the JAKi and IL-6i groups. Results: After PSM, the observational period was determined to be 605.27 patient-years (PY), and the median observational period was determined to be 2.28 years. We identified seven cases of malignancy (IR: 2.94 per 100 PY) in the JAKi-treated group and five cases (IR: 1.36 per 100 PY) in the IL-6i-treated group after PSM. The IR of MACEs was 2.56 and 0.83 (per 100 PY) in the JAKi- and IL-6i-treated groups. The IRRs of JAKi-treated patients versus IL-6i-treated patients were 2.13 (95% confidence interval (CI): 0.67-7.42) for malignancy and 3.03 (95% CI: 0.77-15.21) for MACE. There were no significant differences in IRR for malignancy and MACE between both groups after PSM. Univariate and multivariable Cox regression analyses revealed that older age and JAKi use were independent risk factors for malignancy, while older age, hypertension, and JAKi use were independent risk factors for MACEs. The overall malignancy SIR was significantly higher in the JAKi-treated group compared to the general population (2.10/100 PY, 95% CI: 1.23-2.97). Conclusion: The IRs of malignancy and MACE in patients with RA after PSM were comparable between IL-6i-treated and JAKi-treated patients. However, the SIR of malignancy in JAKi treatment was significantly higher than in the general population; therefore, further safety studies comparing JAKi to non-TNFi biologic disease-modifying antirheumatic drugs (bDMARDs) are needed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Yoshida, S., Miyata, M., Suzuki, E., Kanno, T., Sumichika, Y., Saito, K., Matsumoto, H., Temmoku, J., Fujita, Y., Matsuoka, N., Asano, T., Sato, S., & Migita, K. (2023). Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study. Frontiers in Immunology, 14, 1267749. https://doi.org/10.3389/fimmu.2023.1267749
MLA 9
Yoshida, Shuhei, et al. “Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.” Frontiers in Immunology, vol. 14, 2023, p. 1267749. https://doi.org/10.3389/fimmu.2023.1267749.
Chicago
Yoshida, Shuhei, Masayuki Miyata, Eiji Suzuki, Takashi Kanno, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, et al. 2023. “Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.” Frontiers in Immunology 14: 1267749. https://doi.org/10.3389/fimmu.2023.1267749.
Harvard
Yoshida, S. et al. (2023) ‘Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study’, Frontiers in Immunology, 14, p. 1267749. doi:10.3389/fimmu.2023.1267749.
IEEE
S. Yoshida et al., “Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study,” Frontiers in Immunology, vol. 14, p. 1267749, 2023, doi: 10.3389/fimmu.2023.1267749.
BibTeX
@article{yoshida2023safety,
title = {{Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study}},
author = {Yoshida, Shuhei and Miyata, Masayuki and Suzuki, Eiji and Kanno, Takashi and Sumichika, Yuya and Saito, Kenji and Matsumoto, Haruki and Temmoku, Jumpei and Fujita, Yuya and Matsuoka, Naoki and Asano, Tomoyuki and Sato, Shuzo and Migita, Kiyoshi},
journal = {Frontiers in Immunology},
year = {2023},
volume = {14},
pages = {1267749},
doi = {10.3389/fimmu.2023.1267749},
url = {https://doi.org/10.3389/fimmu.2023.1267749}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 7 | |
| 2025 | 6 | |
| 2026 | 11 |
Its field-weighted citation impact is 4.00: it has been cited 4.00 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- IL-6 inhibitors
- tofacitinib
- cancer risk
- major adverse cardiovascular events
- drug safety
- standardized incidence ratio
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Yoshida, S., Miyata, M., Suzuki, E., Kanno, T., Sumichika, Y., Saito, K., Matsumoto, H., Temmoku, J., Fujita, Y., Matsuoka, N., Asano, T., Sato, S., & Migita, K. (2023). Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study. Frontiers in Immunology, 14, 1267749. https://doi.org/10.3389/fimmu.2023.1267749
How many times has this paper been cited?
24 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Shuhei Yoshida, Masayuki Miyata, Eiji Suzuki, Takashi Kanno, Yuya Sumichika, Kenji Saito, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato and 1 more.
What is the DOI of this paper?
10.3389/fimmu.2023.1267749, permanently at https://doi.org/10.3389/fimmu.2023.1267749. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.